|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 366.68 USD | +0.11% |
|
+1.67% | +11.96% |
| 06:37pm | Goldman Sachs Adjusts Price Target on Amgen to $427 From $425, Maintains Buy Rating | MT |
| 16/07 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,26,718 | 1,40,139 | 1,54,142 | 1,40,103 | 1,76,250 | 1,97,690 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 12.16% | - | - |
| Enterprise Value (EV) 1 | 1,51,990 | 1,69,779 | 2,07,811 | 1,88,229 | 2,21,725 | 2,39,631 | 2,33,980 | 2,29,258 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 8.08% | -2.36% | -2.02% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 24x | 22x | 21.2x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 18.5x | 15.5x | 12.8x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 3.36x | 2.43x | 5.29x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 5.24x | 5.11x | 4.97x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 6.35x | 6.05x | 5.77x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 11.2x | 10.9x | 11x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 14.5x | 13.8x | 13.1x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 18.9x | 15.5x | 15x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 5.3% | 6.46% | 6.65% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.75% | 2.91% | 3.04% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.25 | 16.63 | 17.29 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 66.2% | 64.1% | 64.3% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 37,749 | 38,681 | 39,738 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,359 | 21,472 | 20,861 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,489 | 16,993 | 17,480 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,219 | 8,851 | 9,284 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,942 | 36,290 | 31,568 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 366.29 | 366.29 | 366.29 |
| Nbr of stocks (in thousands) | 5,63,266 | 5,33,579 | 5,35,178 | 5,37,533 | 5,38,481 | 5,39,708 | - | - |
| Announcement Date | 07/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 24.02x | 6.35x | 11.22x | 2.75% | 20TCr | |
| 35.04x | 12.53x | 26.21x | 0.57% | 1,05100Cr | |
| 27.19x | 6.2x | 16.98x | 2.12% | 61TCr | |
| 33.15x | 7.52x | 15.43x | 2.7% | 45TCr | |
| 17.85x | 4.43x | 10.91x | 3% | 33TCr | |
| 21.66x | 5.55x | 13.44x | 2.84% | 28TCr | |
| 21.16x | 4.46x | 12.34x | 1.97% | 26TCr | |
| 14.45x | 5.41x | 11.15x | 3.44% | 22TCr | |
| -48.37x | 5.78x | 31.95x | 2.42% | 17TCr | |
| 12.72x | 3.11x | 7.86x | 6.89% | 14TCr | |
| Average | 15.89x | 6.13x | 15.75x | 2.87% | 37.18TCr | |
| Weighted average by Cap. | 23.58x | 7.64x | 17.93x | 2.19% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
